Tenderwize
Retour à la recherche

Open house discount agreements Pegfilgrastim ATC L03AA13

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Oct 03, 2027 · 400 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Pegfilgrastim, ATC L03AA13

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

The discount agreement does not commit AOK Bayern to purchase any volume. The commercial benefit depends entirely on pr...

If a national or regional framework agreement for Pegfilgrastim is concluded through a formal procurement, the open-hou...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Supply of pharmaceutical products containing Pegfilgrastim (ATC L03AA13)
  • Non-exclusive discount agreements (Rabattverträge) under §130a Abs. 8 SGB V
Afficher le résumé complet

This is an open-house model (not a standard procurement procedure) by AOK Bayern for non-exclusive discount agreements on the active substance Pegfilgrastim (ATC L03AA13). All eligible pharmaceutical companies can enter into identical, non-negotiable discount agreements. The contract period is from 1 December 2025 to 30 November 2027, with any-time joining possible until 3 October 2027. No estimated value is provided. The procedure is not subject to procurement law, and no selection/award criteria apply – participation is open to all qualified pharmaceutical undertakings.

Risques

The discount agreement does not commit AOK Bayern to purchase any volume. The commercial benefit depends entirely on pr...

If a national or regional framework agreement for Pegfilgrastim is concluded through a formal procurement, the open-hou...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical undertakings (pharmazeutische Unternehmen) are eligible to participate

Administrative

  • Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Submission of the signed contract including an annex listing the specific medicinal products

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house discount agreements Pegfilgrastim ATC L03AA13

Non-exclusive discount agreement for the active substance Pegfilgrastim (ATC L03AA13) with AOK Bayern. All eligible pharmaceutical companies can join at any time during the contract period.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Nov 2025 - Nov 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Oct 03, 2027

Détails de la procédure

Date de publication
13 Oct 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
673779-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30